These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12000818)

  • 21. [Acetylsalicylic acid does not prevent cardiovascular disease. Poor scientific support for therapeutic guidelines according to primary prevention studies].
    Mooe T
    Lakartidningen; 2006 Sep 20-26; 103(38):2732-6. PubMed ID: 17058766
    [No Abstract]   [Full Text] [Related]  

  • 22. [Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].
    Rollini F; Franchi F; Angiolillo DJ
    G Ital Cardiol (Rome); 2015 May; 16(5):277-80. PubMed ID: 25994462
    [No Abstract]   [Full Text] [Related]  

  • 23. [After the disappointing ASS primary prevention trial. "Holding back in women"].
    Rupprecht HJ
    MMW Fortschr Med; 2005 Mar; 147(12):13. PubMed ID: 15832783
    [No Abstract]   [Full Text] [Related]  

  • 24. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland.
    Rodondi N; Cornuz J; Marques-Vidal P; Butler J; Hayoz D; Pécoud A; Paccaud F; Waeber G; Vollenweider P
    Prev Med; 2008 Feb; 46(2):137-44. PubMed ID: 17904211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin for prevention of myocardial infarction.
    Mirvis DM
    J Tenn Med Assoc; 1995 Oct; 88(10):392-4. PubMed ID: 7475013
    [No Abstract]   [Full Text] [Related]  

  • 27. [Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct].
    Di Pasquale G; Ottani F; Ceré E; Biancoli S; Sassone B; Lombardi A
    Recenti Prog Med; 1998 Oct; 89(10):514-9. PubMed ID: 9842255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
    Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
    Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
    Minerva Med; 2003 Apr; 94(2):XIII-IV. PubMed ID: 12916522
    [No Abstract]   [Full Text] [Related]  

  • 32. Clopidogrel for preventing cardiovascular events.
    Stulman J; McGinn T; Korenstein D
    Mt Sinai J Med; 2009 Apr; 76(2):194-7. PubMed ID: 19306382
    [No Abstract]   [Full Text] [Related]  

  • 33. An intervention to improve secondary prevention of coronary heart disease.
    Bailey TC; Noirot LA; Blickensderfer A; Rachmiel E; Schaiff R; Kessels A; Braverman A; Goldberg A; Waterman B; Dunagan WC
    Arch Intern Med; 2007 Mar; 167(6):586-90. PubMed ID: 17389290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
    Mikkelsson J; Eskola M; Nikus K; Karhunen PJ; Niemela K
    Ann Med; 2008; 40(4):296-302. PubMed ID: 18428022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
    Prescrire Int; 2000 Jun; 9(47):89-90. PubMed ID: 11010752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kawasaki disease.
    Shulman ST; Bendet M
    Compr Ther; 1997 Jan; 23(1):13-8. PubMed ID: 9067077
    [No Abstract]   [Full Text] [Related]  

  • 37. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Female, young, healthy. ASS does not protect from myocardial infarct].
    MMW Fortschr Med; 2005 Mar; 147(12):10. PubMed ID: 15832782
    [No Abstract]   [Full Text] [Related]  

  • 39. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions.
    Nicolucci A; De Berardis G; Sacco M; Tognoni G
    Eur Heart J; 2007 Aug; 28(16):1925-7. PubMed ID: 17604291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.